Publications by authors named "Milagros Salvani-Bautista"
Background: Though observational evidence supports indirect effects of SARS-CoV-2 vaccines, randomised experiments are lacking. To address this gap, the double-blinded, prospective follow-up of the household contacts (HHCs) of Philippine participants of the individually-randomised, placebo-controlled trial of the adjuvanted-subunit protein COVID-19 vaccine, SCB-2019, (EudraCT, 2020-004272-17; ClinicalTrials.gov, NCT04672395) was analyzed in a cluster-randomised fashion.
View Article and Find Full Text PDFArticle Synopsis
- SCB-2019, a COVID-19 vaccine candidate, was tested in a study involving 1,278 healthy adolescents aged 12-17 across Belgium, Colombia, and the Philippines to evaluate its immunogenicity and safety compared to placebo.
- The vaccine showed strong immunogenicity, with neutralizing antibody levels in adolescents comparable to those in young adults, particularly for those previously exposed to SARS-CoV-2.
- The SCB-2019 vaccine was well tolerated, with mild to moderate side effects that were similar between adolescents receiving the vaccine and those given a placebo, except for more reported injection site pain in the vaccine group.
Article Synopsis
- The study evaluated the safety and efficacy of the SCB-2019 COVID-19 vaccine in a large, double-blind, placebo-controlled trial involving over 30,000 adults across five countries.* -
- Participants were randomly assigned to receive either the vaccine or a placebo, and the primary focus was on measuring vaccine effectiveness against COVID-19 and monitoring adverse effects.* -
- Results showed that the vaccine had an overall efficacy of 67.2% against any severity of COVID-19, and 83.7% efficacy against moderate-to-severe cases, indicating its potential effectiveness in preventing the disease.*